Cannabis stocks have show tremendous volatility this week as the retail investor revolution hit the cannabis industry. However, Martin believes the real cannabis story has to do with company fundamentals, which he sees improving as Aurora focuses on its high-margin medical cannabis business.
"Medical cannabis is really the foundation of what Aurora is all about, we had a great quarter in Canada and internationally," Martin told TheStreet.
While medical cannabis revenue was up 42% year over year and 16% sequentially, consumer cannabis revenue however fell sequentially, which the company also plans on addressing.
"First and foremost is improving the overall quality of our products... Secondly is the launch of new products... Third is a focus on premium products and market accretive products... we think we will be on the path to grow our recreation business," Martin said.
The firm is also bullish on the regulatory landscape in the U.S. with Democrats controlling both houses of Congress as well as the White House.
"The same reason we have been able to get into markets like Germany and Israel and Poland and the Czech Republic because of FD compliance," Martin said.